About us

At Phagenesis, we’re transforming the future of neurogenic dysphagia treatment

Built on pioneering research into the brain-to-swallow connection, Phagenesis is a leader in delivering targeted pharyngeal electrical stimulation to restore neural pathways for safe, efficient swallowing

Our Vision

At Phagenesis, our vision is to transform the treatment of neurogenic dysphagia worldwide by restoring the brain-to-swallow connection, improving recovery, and reducing the burden of care for patients, families, and healthcare systems.

Leadership

chad Hoskins
Chief Executive Officer
CONOR MULROONEY
Co-Founder & Chief Operating Officer
MARC KORENBERG
Chief Financial Officer
SHAHEEN HAMDY
Co-Founder & Chief Scientific Officer
BUCK WELLER
VP US Sales
BORIS DEUTSCHMANN
Director European Sales
MADDY SADIQ
Head of Human Resources

Board of Directors

OERN STUGE
Chairperson, Director Chairperson Orsco Lifesciences AG
FRED EDENIUS
Director
Founder / Director Scientific Venture Partners
MICHEL GARDET
Director
Independent Advisor
CHAD HOSKINS
Director
CEO Phagenesis
DREW BURDON
Director Partner EQT Lifesciences
James Gibbons
Director
Investment Manager Northern Gritstone
MICHAEL SJÖSTRÖM
Director
Co-founder / Partner Sectoral Asset Management

Leading the Past, Pioneering the Future

Pioneering Brain Mapping of Swallow Function
First to map the swallow motor cortex in both healthy individuals and patients with disease, laying the foundation for understanding the neural control of swallowing
Linking Brain Reorganization to Dysphagia Recovery
First to demonstrate that recovery from dysphagia is associated with functional reorganization of the swallow motor cortex
Proving Short-Term Stimulation Drives Long-Term Brain Change
First to show that brief sensory stimulation can trigger lasting reorganization of the cortex involved in swallowing
Connecting Sensory Stimulation to Swallow Function Recovery
First to establish that sensory stimulation-induced brain reorganization leads to meaningful improvements in swallowing ability

Clinical Evidence

25 Years

Backed by over two decades of research supporting our proven mechanism of action

9 Trials

Validated through randomized clinical trials showing consistent safety, efficacy, and patient outcomes

30+ Publications

Supported by independent, peer-reviewed studies that meet rigorous scientific standards

Interested in transforming the future of neurogenic dysphagia treatment?

Explore careers
MADDY SADIQ
Head of Human Resources

A seasoned HR leader with over 15 years of experience in talent acquisition and human capital strategy. She has held key roles at QIAGEN, a global leader in Biotech. Maddy is passionate about building inclusive, high-performing teams and driving organizational success through strategic people practices.

BORIS DEUTSCHMANN
Director European Sales

Tech enthusiast and entrepreneur passionate about transforming care for underserved patients. Proven Sales Leader with a track record of driving success in Europe’s medtech market, launching cutting-edge solutions for startups and industry giants like Mainstay Medical, Nevro, and Abbott (St. Jude Medical).

BUCK WELLER
VP US Sales

A proven sales and business development leader specializing in launching innovative technologies and driving rapid growth in early-stage companies. With a track record of building high-performing teams, he combines strategic vision and customer-focused leadership to deliver exceptional results.

SHAHEEN HAMDY
Co-Founder & Chief Scientific Officer

Professor of Neurogastroenterology and inventor. Focused on advancing the neuroscience of swallowing control through research on neuroplasticity and functional recovery following brain injury. One of the highest cited academics in the field of dysphagia.

MARC KORENBERG
Chief Financial Officer

Proven Medtech and Biotech executive with nearly two decades of strategic finance and operational experience bringing companies from clinical and R&D stages to commercial scale. Prior experience in roles with UBS Investment Bank, Zeltiq Aesthetics Inc. (Acquired by Allergan) and Revance Therapeutics Inc. (acquired by Crown Laboratories).

CONOR MULROONEY
Co-Founder & Chief Operating Officer

Operations leader and inventor. Molecular biology, process automation and technical management expertise. Lead inventor on 50+ patents. Innovation driven with a focus on real-world solutions.

chad Hoskins
Chief Executive Officer

An accomplished executive leader with over two decades of experience launching cutting-edge medical technologies. Prior experience includes leadership roles with Axon Therapies, Outset Medical, Abbott, Thoratec and McKinsey & Co.

Kate Ecklund

VP Clinical Affairs
An innovative, solution-driven leader with over 15 years of experience in designing and leading high-impact global trials that bring novel therapies to market and improve patient lives. Prior experience at Medtronic, Surmodics, Mainstay Medical, and Alucent Biomedical and across multiple therapy areas.

Stephen Halstead

Head of QA/RA
Experienced multinational medical device Quality professional with a steadfast commitment to continuous improvement of global Quality Management Systems and processes. A track record of scaling international operations and businesses to meet and exceed critical growth objectives.

Cari Manypenny

Head of Global Education
Dedicated medical speech-language pathologist and educator. Extensive experience in patient care, clinical education, and research. Committed to enhancing patient care and improving the lives of people with dysphagia.

Anil Keni

VP Global Marketing
Marketing leader with strong background in engineering and sales. Years of commercialization experience at highly reputable companies (Edwards, Abbott, STORZ). Committed to serving patients with a start-up work ethic and a ‘can-do’ mindset.

Scott Grant

VP US Therapy Development
Market development professional with decades of commercial success in emerging and established companies (Guidant, Abbott). Driven to bring innovation safely and effectively to market.

Andre Nel

Chief Financial Officer
Dynamic CFO with over 20 years of international experience, specializing in global scaling, financial leadership, and sustainable growth, with expertise in IPO readiness, market expansion, and risk management.